CardioQ update

Deltex Medical Group PLC
02 April 2008


                            Deltex Medical Group plc

First protocols for routine use of the CardioQ(TM) in intensive care established
at leading acute hospital in the USA


2 April 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, today announces that intensive care doctors at
a leading acute hospital in southern California have formally implemented care
protocols for monitoring patients in intensive care using the CardioQ.

After the successful implementation of routine use in surgery at the hospital,
doctors responsible for patients in intensive care (ICU), whether
post-operatively or for medical reasons, undertook a short evaluation of the
CardioQ to determine how to best to integrate it into ICU care protocols.

Based on the results of this evaluation, draft protocols were submitted to and
accepted by the critical care committee for approval and inclusion in the
hospital's clinical and management information system with immediate effect.

Deltex Medical's Chief Executive, Andy Hill commented:

'The integration of the CardioQ as a monitor for routine, protocol-driven use in
intensive care means that doctors need no longer use more invasive and unproven
technologies for determining cardiac output in the vast majority of patients
needing monitoring.'


For further information, please contact:-

Deltex Medical Group plc                 01243 774 837
Nigel Keen, Chairman                     [e-mail]
Andy Hill, Chief Executive               [e-mail]
Ewan Phillips, Finance Director          [e-mail]

Gavin Anderson & Company                 0207 554 1400
Deborah Walter                           [e-mail]
Robert Speed                             [e-mail]

Charles Stanley Securities
Nominated Advisors                       020 7149 6000
Philip Davies                            [e-mail]
Russell Cook                             [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to optimise
critically ill patients and those undergoing routine moderate to major surgery
through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been proven to improve the speed and quality of patient
recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange